A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder

1991615 citationsJournal Articlebronze Open Access

Authors

As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer.

Good health and well-being

Published in: New England Journal of Medicine

Volume 325, Issue 17, pp. 1205-1209

Field-Weighted Citation Impact: 22.91